AstraZeneca, Daiichi Sankyo Submit Biologics License Application of Datopotamab Deruxtecan for Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer
Decision to submit the Biologics License Application of datopotamab deruxtecan was based on feedback from a previously withdrawn application to the FDA for nonsquamous non-small cell lung cancer.
